To provide the information your oncologist is not telling you or doesn't have the time to!
Explore a comprehensive range of insights and information within our ‘Varied Cancer Perspectives’ category. From melanoma to breast cancer, colorectal cancer to sarcoma, and beyond, this diverse collection delves into the multifaceted world of oncology. Gain a nuanced understanding of different cancer types, treatments, and the latest advancements in research. Whether you’re seeking knowledge on pediatric oncology, uveal melanoma, or desmoid tumors, our curated content provides a holistic view, offering valuable perspectives to empower and inform those navigating the complexities of cancer care. Join us on a journey through varied perspectives, ensuring a well-rounded understanding of the ever-evolving landscape of cancer.
On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco (Bizengri), marking a significant milestone in cancer care. This is the first approved systemic therapy targeting NRG1 gene fusions, a rare but actionable driver mutation in certain cancers. Zenocutuzumab-zbco is approved for adults with: This approval offers a new, precision-medicine option for patients with …
Colorectal cancer remains a significant global health challenge, ranking as the third most common cancer and the second leading cause of cancer-related deaths worldwide. Among metastatic colorectal cancer patients, the subset with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) tumors presents unique opportunities for immunotherapy. The recent CheckMate 8HW trial, published in the New England Journal …
For patients with advanced melanoma who have exhausted standard treatment options, new therapies offer much-needed hope. On November 21, 2024, Replimune Group, Inc. announced that its breakthrough oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), in combination with nivolumab, received Breakthrough Therapy Designation from the FDA. The FDA also accepted a Biologics License Application (BLA) for RP1 under …
On November 20, 2024, the FDA granted accelerated approval to zanidatamab-hrii (Ziihera), a bispecific HER2-directed antibody, for the treatment of previously treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC). This decision brings new hope for patients battling this aggressive and hard-to-treat disease, offering a targeted option for a population with limited therapeutic choices. The …
Radiation therapy has long been a cornerstone in the treatment of various cancers, including gastric cancer, particularly for locally advanced or high-risk cases. However, the evolving landscape of gastric cancer management has raised questions about the necessity of adding preoperative chemoradiotherapy to standard perioperative chemotherapy. The recently published TOPGEAR trial sheds new light on this …
In the world of oncology, the old adage holds true: “When tumors are the rumors and cancer is possibly the answer, then tissue is the issue.” This highlights the critical role of biopsy in uncovering the true nature of suspicious lesions. Hepatic tumors, in particular, pose a diagnostic challenge because they encompass a broad spectrum …
Colon cancer treatments have long relied on surgery, chemotherapy, and radiation. However, recent breakthroughs in immunotherapy, particularly for mismatch repair–deficient (dMMR) tumors, are reshaping how certain high-risk cancers are treated. A recent study published in The New England Journal of Medicine provides encouraging data on the effectiveness of neoadjuvant immunotherapy for patients with locally advanced dMMR colon …
For patients with a specific type of breast cancer—hormone receptor-positive, HER2-negative—that also carries a PIK3CA mutation, a new combination treatment shows promising results. The treatment combines inavolisib, a targeted therapy, with palbociclib and fulvestrant, helping to significantly slow disease progression compared to standard treatment. This combination not only targets multiple cancer growth pathways but also …
Lung cancer remains one of the most common and deadly cancers worldwide. Smoking is responsible for approximately half of all lung cancer cases, making it the single most preventable cause of this disease. For individuals who have smoked for years, quitting can be difficult, and many turn to alternatives like electronic cigarettes (e-cigarettes) as a …
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive and challenging types of thyroid cancer. Known for its rapid growth, resistance to conventional therapies, and poor prognosis, ATC has historically had limited treatment options. However, recent studies, including groundbreaking research by Dr. Maria Cabanillas and colleagues at MD Anderson Cancer Center, have highlighted the …